TRAF inhibition drives cancer cell apoptosis and improves retinoic acid sensitivity in multiple cancers models

Kun Zhong1, Xiaojun Liu1, Weihua Ding1

  • 1Medical School, Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu Province, People's Republic of China.

Discover Oncology
|June 30, 2023
PubMed

Insights

This study shows that inhibiting TNF receptor-associated factors (TRAFs) enhances cancer cells

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • TNF receptor-associated factors (TRAFs) are key signaling adaptors involved in cellular pathways, survival, and cancer.
  • 13-cis-retinoic acid (RA), a vitamin A metabolite, has anti-cancer effects, but resistance limits its clinical use.
  • Understanding factors influencing RA sensitivity is crucial for improving cancer therapy.

Purpose of the Study:

  • To investigate the association between TRAF expression and retinoic acid sensitivity in various cancers.
  • To explore the therapeutic potential of combining RA with TRAF inhibition.

Main Methods:

  • Analyzed TRAF expression across TCGA cancer cohorts and cell lines.
  • Inhibited TRAF4, TRAF5, or TRAF6 in ovarian cancer and melanoma cell lines and xenografts.
  • Assessed effects on RA sensitivity, colony formation, apoptosis (procaspase 9 levels), and in vivo tumor growth.

Main Results:

  • TRAF expression levels differed significantly across cancer types.
  • Inhibiting TRAF4, TRAF5, or TRAF6 enhanced RA sensitivity and reduced colony formation in ovarian cancer and melanoma.
  • TRAF knockdown increased procaspase 9 and induced apoptosis in RA-treated cancer cells, with confirmed anti-tumor effects in vivo.

Conclusions:

  • TRAF proteins are linked to retinoic acid resistance in cancers.
  • Silencing TRAF4, TRAF5, or TRAF6 potentiates the anti-cancer effects of retinoic acid.
  • Combination therapy with retinoic acid and TRAF silencing shows promise for treating ovarian cancer and melanoma.

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K